logo

Moehs BCN

 Zenc, 12 – 08755 Castellbisbal, Barcelona, España
Tel: +34 935 860 520

MOEHS BCN, SL is the new production plant of the MOEHS GROUP. It is located in the municipality of Castellbisbal, 30 km from Barcelona and 10 km from the Moehs Catalana plant.

Its total area is 28,750 m². The production building has a total area of 4,500 m², the treatment plant 2,210 m² and warehouses 2,930 m². Laboratories, offices and workshop complete the built area with 3,900 m².

Synthesis

The síntesis area ocupéis 3 floors of the Production bilding. It is equipped whit enamelied or stainless steel mult-purpose reactor, wiht capacities from 630 to 10.000 litres centrifuges and grinding columns for solvent recovery. The total volumen reaction rate is 100 m3

Purified

The purified area of MOEHS BCN consists of 4 crystallization units and 4 finishing units – all clean rooms class D, equipped with filtered air overpressure – equipped with equipment equivalent to the rest of the group’s plants and operating in accordance with GMP.

Future enlargements

MOEHS BCN’s design has predicted the future growth of the group. The facilities can be extended to a reaction capacity of 300 m³. For this, a 3,300 m³ zone has been reserved next to the Production building.

Steam

5.000 KG/H (7 bars)

Cold

3500,000 KFRIG/H

Pressure

-1 a Patm

Temperature

-85 a 140 ºC

NITROGEN. 
Total reaction capacity: 100 m³.

logo
Twitter Linkedin-in
  • Headquarters:
  • Pol. Ind. Cova Solera
  • c/Roma, 8-12 08191 Rubí.
  • Barcelona (Spain)
  • T +34 93 586 05 20
  • Fax +34 93 588 85 13
  • info@moehs.es

Partnering companies

The Board of Directors of the Center for Technological Development and Innovation, E.P.E (CDTI), in its meeting held on 02/23/2023, approved the participation of this center in the research and development project called SYNTHESIS OF A STIMULATOR ACTIVE PRINCIPLE OF SOLUBLE CYCLASE GUANYLATE by granting partially reimbursable aid.

The objective is focused on the development of a new method of chemical synthesis of an active ingredient that stimulates soluble guanylate cyclase.

The project will be carried out at the Rubí facilities. The project execution period is from 2022 to 2024 and they have a financeable budget of €1,862,213.00.
This project is co-financed by the European Union and CDTI.

The Board of Directors of the Center for Technological Development and Innovation, E.P.E (CDTI), in its meeting held on 02/23/2023, approved the participation of this center in the research and development project called SYNTHESIS OF AN ACTIVE INHIBITOR PRINCIPLE OF JANUS KINASE FOR THE TREATMENT OF ATOPIC DERMATITIS.”, by granting partially reimbursable aid.

The objective is focused on the development of a new method of chemical synthesis of a janus kinase inhibitor active ingredient for the treatment of atopic dermatitis.

The project will be carried out at the Rubí facilities. The project execution period is from 2022 to 2025 and they have a financeable budget of €1,940,409.
This project is co-financed by the European Union and CDTI.